Contact
searchSearch
HMP Global

Drug Recalls Topic Center

The Latest

News
Memantine Hydrochloride Capsules Recalled for Failed Dissolution Specifications
04/23/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for memantine hydrochloride capsules due to failure to meet dissolution specifications.
The US Food and Drug Administration (FDA) has issued a Class II recall for memantine hydrochloride capsules due to failure to meet dissolution specifications.
The US Food and Drug...
04/23/2026
Pharmacy Learning Network
News
Semaglutide-Glycine-Cyanocobalamin Injectables Recalled for Lack of Sterility Assurance
04/23/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for semaglutide-glycine-cyanocobalamin injectable due to sterility assurance concerns, affecting 91 units.
The US Food and Drug Administration (FDA) has issued a Class II recall for semaglutide-glycine-cyanocobalamin injectable due to sterility assurance concerns, affecting 91 units.
The US Food and Drug...
04/23/2026
Pharmacy Learning Network
News
Essential Calming Skin Gel Recalled for Subpotent Drug
04/23/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class III recall for Essential Calming Skin Gel due to subpotent drug, affecting nearly 300 units.
The US Food and Drug Administration (FDA) has issued a Class III recall for Essential Calming Skin Gel due to subpotent drug, affecting nearly 300 units.
The US Food and Drug...
04/23/2026
Pharmacy Learning Network
News
Albuterol Sulfate Inhalation Solution Recalled for Illegible Labeling
04/16/2026
Hannah Musick
The US Food and Drug Administration (FDA) has issued a Class II recall for albuterol sulfate inhalation solution due to illegible labeling, affecting more than 146 000 unit-dose vials used in respiratory care.
The US Food and Drug Administration (FDA) has issued a Class II recall for albuterol sulfate inhalation solution due to illegible labeling, affecting more than 146 000 unit-dose vials used in respiratory care.
The US Food and Drug...
04/16/2026
Pharmacy Learning Network
News
Epinephrine Injection Recalled for Lack of Sterility Assurance
04/16/2026
Hannah Musick
The US Food and Drug Administration (FDA) has issued a Class II recall for epinephrine injection due to sterility assurance concerns, affecting more than 80 000 units used in emergency care settings.
The US Food and Drug Administration (FDA) has issued a Class II recall for epinephrine injection due to sterility assurance concerns, affecting more than 80 000 units used in emergency care settings.
The US Food and Drug...
04/16/2026
Pharmacy Learning Network
News
Cipla Cinacalcet Tablets Recalled for Nitrosamine Impurity Above Acceptable Limits
04/16/2026
Hannah Musick
The US Food and Drug Administration (FDA) has issued a Class II recall for multiple strengths of Cipla’s cinacalcet tablets due to nitrosamine impurity levels exceeding safety limits, raising concerns for long-term use in dialysis patients.
The US Food and Drug Administration (FDA) has issued a Class II recall for multiple strengths of Cipla’s cinacalcet tablets due to nitrosamine impurity levels exceeding safety limits, raising concerns for long-term use in dialysis patients.
The US Food and Drug...
04/16/2026
Pharmacy Learning Network
News
Xanax XR Tablets Recalled for Dissolution Failure
04/09/2026
Hannah Musick
The US Food and Drug Administration (FDA) has issued a Class II recall for Xanax XR tablets after testing revealed failed dissolution specifications, potentially affecting consistent drug release in patients treated for panic disorder.
The US Food and Drug Administration (FDA) has issued a Class II recall for Xanax XR tablets after testing revealed failed dissolution specifications, potentially affecting consistent drug release in patients treated for panic disorder.
The US Food and Drug...
04/09/2026
Pharmacy Learning Network
News
Cipla Lanreotide Injection Recalled for Lack of Sterility Assurance
04/09/2026
Hannah Musick
A Class II recall is in effect for Cipla’s lanreotide injection prefilled syringes due to sterility assurance concerns tied to manufacturing inspection deficiencies.
A Class II recall is in effect for Cipla’s lanreotide injection prefilled syringes due to sterility assurance concerns tied to manufacturing inspection deficiencies.
A Class II recall is in effect...
04/09/2026
Pharmacy Learning Network
News
Class II Recall for Tramadol Hydrochloride Due to Nitrosamine Impurity Above Specifications
04/09/2026
Hannah Musick
The US Food and Drug Administration (FDA) has issued a Class II recall for tramadol tablets after stability testing detected a nitrosamine impurity above acceptable limits, raising concerns about long-term exposure.
The US Food and Drug Administration (FDA) has issued a Class II recall for tramadol tablets after stability testing detected a nitrosamine impurity above acceptable limits, raising concerns about long-term exposure.
The US Food and Drug...
04/09/2026
Pharmacy Learning Network
News
Macleods Recalls Levothyroxine Sodium Tablets Due to Subpotency
04/02/2026
Hannah Musick
Macleods Pharma USA, Inc is recalling one lot of levothyroxine sodium tablets 150 mcg nationwide after testing identified subpotent drug levels that may reduce therapeutic effectiveness.
Macleods Pharma USA, Inc is recalling one lot of levothyroxine sodium tablets 150 mcg nationwide after testing identified subpotent drug levels that may reduce therapeutic effectiveness.
Macleods Pharma USA, Inc is...
04/02/2026
Pharmacy Learning Network
News
Class II Recall Issued for Poractant Alfa Over Sterility Concerns
04/02/2026
Hannah Musick
Chiesi USA, Inc is recalling select lots of CUROSURF (poractant alfa) intratracheal suspension due to lack of sterility assurance, potentially increasing the risk of contamination in a critical neonatal therapy.
Chiesi USA, Inc is recalling select lots of CUROSURF (poractant alfa) intratracheal suspension due to lack of sterility assurance, potentially increasing the risk of contamination in a critical neonatal therapy.
Chiesi USA, Inc is recalling...
04/02/2026
Pharmacy Learning Network

Newsfeed

News
Memantine Hydrochloride Capsules Recalled for Failed Dissolution Specifications
04/23/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for memantine hydrochloride capsules due to failure to meet dissolution specifications.
The US Food and Drug Administration (FDA) has issued a Class II recall for memantine hydrochloride capsules due to failure to meet dissolution specifications.
The US Food and Drug...
04/23/2026
Pharmacy Learning Network
News
Semaglutide-Glycine-Cyanocobalamin Injectables Recalled for Lack of Sterility Assurance
04/23/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for semaglutide-glycine-cyanocobalamin injectable due to sterility assurance concerns, affecting 91 units.
The US Food and Drug Administration (FDA) has issued a Class II recall for semaglutide-glycine-cyanocobalamin injectable due to sterility assurance concerns, affecting 91 units.
The US Food and Drug...
04/23/2026
Pharmacy Learning Network
News
Essential Calming Skin Gel Recalled for Subpotent Drug
04/23/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class III recall for Essential Calming Skin Gel due to subpotent drug, affecting nearly 300 units.
The US Food and Drug Administration (FDA) has issued a Class III recall for Essential Calming Skin Gel due to subpotent drug, affecting nearly 300 units.
The US Food and Drug...
04/23/2026
Pharmacy Learning Network
News
Albuterol Sulfate Inhalation Solution Recalled for Illegible Labeling
04/16/2026
Hannah Musick
The US Food and Drug Administration (FDA) has issued a Class II recall for albuterol sulfate inhalation solution due to illegible labeling, affecting more than 146 000 unit-dose vials used in respiratory care.
The US Food and Drug Administration (FDA) has issued a Class II recall for albuterol sulfate inhalation solution due to illegible labeling, affecting more than 146 000 unit-dose vials used in respiratory care.
The US Food and Drug...
04/16/2026
Pharmacy Learning Network
News
Epinephrine Injection Recalled for Lack of Sterility Assurance
04/16/2026
Hannah Musick
The US Food and Drug Administration (FDA) has issued a Class II recall for epinephrine injection due to sterility assurance concerns, affecting more than 80 000 units used in emergency care settings.
The US Food and Drug Administration (FDA) has issued a Class II recall for epinephrine injection due to sterility assurance concerns, affecting more than 80 000 units used in emergency care settings.
The US Food and Drug...
04/16/2026
Pharmacy Learning Network
News
Cipla Cinacalcet Tablets Recalled for Nitrosamine Impurity Above Acceptable Limits
04/16/2026
Hannah Musick
The US Food and Drug Administration (FDA) has issued a Class II recall for multiple strengths of Cipla’s cinacalcet tablets due to nitrosamine impurity levels exceeding safety limits, raising concerns for long-term use in dialysis patients.
The US Food and Drug Administration (FDA) has issued a Class II recall for multiple strengths of Cipla’s cinacalcet tablets due to nitrosamine impurity levels exceeding safety limits, raising concerns for long-term use in dialysis patients.
The US Food and Drug...
04/16/2026
Pharmacy Learning Network
News
Xanax XR Tablets Recalled for Dissolution Failure
04/09/2026
Hannah Musick
The US Food and Drug Administration (FDA) has issued a Class II recall for Xanax XR tablets after testing revealed failed dissolution specifications, potentially affecting consistent drug release in patients treated for panic disorder.
The US Food and Drug Administration (FDA) has issued a Class II recall for Xanax XR tablets after testing revealed failed dissolution specifications, potentially affecting consistent drug release in patients treated for panic disorder.
The US Food and Drug...
04/09/2026
Pharmacy Learning Network
News
Cipla Lanreotide Injection Recalled for Lack of Sterility Assurance
04/09/2026
Hannah Musick
A Class II recall is in effect for Cipla’s lanreotide injection prefilled syringes due to sterility assurance concerns tied to manufacturing inspection deficiencies.
A Class II recall is in effect for Cipla’s lanreotide injection prefilled syringes due to sterility assurance concerns tied to manufacturing inspection deficiencies.
A Class II recall is in effect...
04/09/2026
Pharmacy Learning Network
News
Class II Recall for Tramadol Hydrochloride Due to Nitrosamine Impurity Above Specifications
04/09/2026
Hannah Musick
The US Food and Drug Administration (FDA) has issued a Class II recall for tramadol tablets after stability testing detected a nitrosamine impurity above acceptable limits, raising concerns about long-term exposure.
The US Food and Drug Administration (FDA) has issued a Class II recall for tramadol tablets after stability testing detected a nitrosamine impurity above acceptable limits, raising concerns about long-term exposure.
The US Food and Drug...
04/09/2026
Pharmacy Learning Network
News
Macleods Recalls Levothyroxine Sodium Tablets Due to Subpotency
04/02/2026
Hannah Musick
Macleods Pharma USA, Inc is recalling one lot of levothyroxine sodium tablets 150 mcg nationwide after testing identified subpotent drug levels that may reduce therapeutic effectiveness.
Macleods Pharma USA, Inc is recalling one lot of levothyroxine sodium tablets 150 mcg nationwide after testing identified subpotent drug levels that may reduce therapeutic effectiveness.
Macleods Pharma USA, Inc is...
04/02/2026
Pharmacy Learning Network
PharmLaw
Purdue Pharma Sentenced in Federal Opioid Case, Finalizing Fraud and Kickback Conspiracy Resolution
04/29/2026
Grace Taylor, MS, MA
Purdue Pharma’s federal sentencing finalizes a landmark opioid case involving fraud and kickback conspiracies, with lasting compliance implications for the pharmaceutical supply chain.
Purdue Pharma’s federal sentencing finalizes a landmark opioid case involving fraud and kickback conspiracies, with lasting compliance implications for the pharmaceutical supply chain.
Purdue Pharma’s federal...
04/29/2026
Pharmacy Learning Network
News
Memantine Hydrochloride Capsules Recalled for Failed Dissolution Specifications
04/23/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for memantine hydrochloride capsules due to failure to meet dissolution specifications.
The US Food and Drug Administration (FDA) has issued a Class II recall for memantine hydrochloride capsules due to failure to meet dissolution specifications.
The US Food and Drug...
04/23/2026
Pharmacy Learning Network
News
Semaglutide-Glycine-Cyanocobalamin Injectables Recalled for Lack of Sterility Assurance
04/23/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for semaglutide-glycine-cyanocobalamin injectable due to sterility assurance concerns, affecting 91 units.
The US Food and Drug Administration (FDA) has issued a Class II recall for semaglutide-glycine-cyanocobalamin injectable due to sterility assurance concerns, affecting 91 units.
The US Food and Drug...
04/23/2026
Pharmacy Learning Network
News
Essential Calming Skin Gel Recalled for Subpotent Drug
04/23/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class III recall for Essential Calming Skin Gel due to subpotent drug, affecting nearly 300 units.
The US Food and Drug Administration (FDA) has issued a Class III recall for Essential Calming Skin Gel due to subpotent drug, affecting nearly 300 units.
The US Food and Drug...
04/23/2026
Pharmacy Learning Network
PharmLaw
Executive Order Targets Accelerated Development and Access Pathways for Psychedelic Therapies in Mental Health
04/21/2026
Hannah Musick
A new executive order directs federal agencies to accelerate the development, review, and potential patient access to investigational psychedelic therapies for serious mental illness, signaling a shift in regulatory and research priorities...
A new executive order directs federal agencies to accelerate the development, review, and potential patient access to investigational psychedelic therapies for serious mental illness, signaling a shift in regulatory and research priorities...
A new executive order directs...
04/21/2026
Pharmacy Learning Network
News
Albuterol Sulfate Inhalation Solution Recalled for Illegible Labeling
04/16/2026
Hannah Musick
The US Food and Drug Administration (FDA) has issued a Class II recall for albuterol sulfate inhalation solution due to illegible labeling, affecting more than 146 000 unit-dose vials used in respiratory care.
The US Food and Drug Administration (FDA) has issued a Class II recall for albuterol sulfate inhalation solution due to illegible labeling, affecting more than 146 000 unit-dose vials used in respiratory care.
The US Food and Drug...
04/16/2026
Pharmacy Learning Network
News
Epinephrine Injection Recalled for Lack of Sterility Assurance
04/16/2026
Hannah Musick
The US Food and Drug Administration (FDA) has issued a Class II recall for epinephrine injection due to sterility assurance concerns, affecting more than 80 000 units used in emergency care settings.
The US Food and Drug Administration (FDA) has issued a Class II recall for epinephrine injection due to sterility assurance concerns, affecting more than 80 000 units used in emergency care settings.
The US Food and Drug...
04/16/2026
Pharmacy Learning Network
News
Cipla Cinacalcet Tablets Recalled for Nitrosamine Impurity Above Acceptable Limits
04/16/2026
Hannah Musick
The US Food and Drug Administration (FDA) has issued a Class II recall for multiple strengths of Cipla’s cinacalcet tablets due to nitrosamine impurity levels exceeding safety limits, raising concerns for long-term use in dialysis patients.
The US Food and Drug Administration (FDA) has issued a Class II recall for multiple strengths of Cipla’s cinacalcet tablets due to nitrosamine impurity levels exceeding safety limits, raising concerns for long-term use in dialysis patients.
The US Food and Drug...
04/16/2026
Pharmacy Learning Network
PharmLaw
CMS Proposes Sweeping Prior Authorization Reforms for Drugs, Expanding Transparency and Electronic Requirements
04/15/2026
Hannah Musick
The Centers for Medicare & Medicaid Services has proposed sweeping reforms to modernize prior authorization for drugs, introducing faster decision timelines, expanded electronic requirements, and new transparency measures that could...
The Centers for Medicare & Medicaid Services has proposed sweeping reforms to modernize prior authorization for drugs, introducing faster decision timelines, expanded electronic requirements, and new transparency measures that could...
The Centers for Medicare &...
04/15/2026
Pharmacy Learning Network
News
Xanax XR Tablets Recalled for Dissolution Failure
04/09/2026
Hannah Musick
The US Food and Drug Administration (FDA) has issued a Class II recall for Xanax XR tablets after testing revealed failed dissolution specifications, potentially affecting consistent drug release in patients treated for panic disorder.
The US Food and Drug Administration (FDA) has issued a Class II recall for Xanax XR tablets after testing revealed failed dissolution specifications, potentially affecting consistent drug release in patients treated for panic disorder.
The US Food and Drug...
04/09/2026
Pharmacy Learning Network

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use